Hetty Carraway, MD

Articles

Emerging Therapies for Treatment of MDS

June 29th 2023

Expert oncologists discuss management strategies for patients with lower-risk MDS considering upcoming treatment options.

Safety and Efficacy of Luspatercept in Frontline Setting in Patients with MDS

June 29th 2023

Oncologists review study design and discuss key safety and efficacy data of the COMMANDS trial investigating luspatercept in frontline setting in patients with lower-risk MDS.

Risk Stratification of MDS

June 26th 2023

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Diagnosing Myelodysplastic Syndromes (MDS)

June 26th 2023

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

Clinical Use of Luspatercept on Patients with Lower-risk MDS

June 22nd 2023

Ralph Boccia, MD, FACP, shares his clinical experience using luspatercept to treat patient with lower-risk MDS.

Frontline Treatment Options for Lower-Risk MDS

June 22nd 2023

Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.

Importance of Early Diagnosis of MDS for Lower and Higher-risk Patients

June 15th 2023

Hetty Carraway, MD, highlights the importance of early diagnosis across all patients with MDS.

Risk Stratification of Myelodysplastic Syndromes [MDS]

June 15th 2023

Ralph Boccia, MD, FACP, and Hetty Carraway, MD, review Myelodysplastic Syndromes [MDS] risk stratification criteria used in their practices.

Future Directions in the Management of Acute Myeloid Leukemia

March 21st 2023

Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.

Emerging Treatment Strategies in Acute Myeloid Leukemia

March 21st 2023

A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.

Sequencing Therapies in Patients With Relapsed/Refractory AML

March 14th 2023

Shared insight on how treatments can be optimally sequenced in patients with relapsed/refractory acute myeloid leukemia.

A Potential Role for IDH-1 Inhibitor Olutasidenib in Relapsed/Refractory AML?

March 14th 2023

Expert perspectives on the potential role of IDH1-targeted therapy, olutasidenib, in patients with relapsed/refractory acute myeloid leukemia.

Treatment Strategies in Patients With Relapsed/Refractory AML

March 7th 2023

Centering its discussion on relapsed/refractory acute myeloid leukemia, the panel highlights broader treatment strategies in this setting.

Role of Stem Cell Transplant in Acute Myeloid Leukemia

March 7th 2023

Before closing out their discussion on first-line treatment options for patients with AML, expert oncologists reflect on the role of stem cell transplant in AML.

Novel Venetoclax-Based Regimens in Patients With AML Unfit for Intensive Chemotherapy

February 28th 2023

A comprehensive review of novel venetoclax-based combination therapy in patients unfit for intensive chemotherapy who are diagnosed with AML.

Frontline Treatment in Patients With IDH-Mutated AML Unfit for Intensive Chemotherapy

February 28th 2023

In the setting of IDH-mutated AML, panelists consider optimal treatment options in patients unfit for intensive chemotherapy.

Acute Myeloid Leukemia: VEN + AZA Treatment in Patients Unfit for Intensive Chemotherapy

February 21st 2023

A brief overview of mainstay treatment options in the first-line setting of AML for patients deemed unfit for intensive chemotherapy.

Optimizing Management of TP53-Mutated Acute Myeloid Leukemia

February 21st 2023

Expert oncologists highlight challenges in the setting of TP53-mutated AML and consider appropriate treatment strategies.

Acute Myeloid Leukemia: Frontline Treatment With CPX-351

February 14th 2023

Comprehensive discussion on the emergence of CPX-351 as a first-line treatment option for patients with acute myeloid leukemia.

Frontline Treatment Options for Patients With IDH2-Mutated AML

February 14th 2023

Shared insight on IDH-mutated acute myeloid leukemia and appropriate first-line treatment options in this setting.